Abstract Library

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#4446 Uncommon ophthalmic presentation of a small bowel neuroendocrine tumour: Case report

Introduction: Neuroendocrine tumours (NETs), including carcinoid tumours, are slow-growing neoplasms commonly originating in the gastrointestinal tract or bronchus, but they can also arise in other sites. Due to their indolent nature, the majority of NETs are diagnosed at an advanced stage, typically to the lymph nodes, liver, or bones.

Conference:

Presenting Author:

Authors: Hamidatou K, Behourah Z, Ahed Messaoud M, Megaiz A, Lechar M,

Keywords: Neuroendocrine tumour, Carcinoid tumour, Orbital metastasis, somatostatin analogue injection,

#4365 Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the stomach: A case report

Introduction: Gastric neuroendocrine tumours (NETs) are rare neoplasms that arise from enterochromaffin cells of the gastric mucosa. Neuroendocrine carcinoma (NEC) of the stomach represent a rare and rapidly growing type of gastric tumour. They are considered a distinct entity from neuroendocrine tumours characterised by aggressive behaviour and a high rate of metastasis.

Conference:

Presenting Author: Zidane H

Authors: Zidane H, Kebbati Z, Benkada M,

Keywords: neuroendocrine carcinoma, stomach, chemotherapy,

#4349 Challenging management of ductal adenocarcinoma of the prostate with neuroendocrine differentiation: A case report

Introduction: Ductal adenocarcinoma of the prostate is a rare subtype of prostate cancer that arises from the ducts of the prostate gland. It is characterised by distinct histological features and a more aggressive clinical course. Neuroendocrine differentiation within this subtype is associated with a more aggressive phenotype and can lead to resistance to conventional androgen deprivation therapies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: neuroendocrine prostate cancer, progression, multidisciplinary approach,